Work

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Year: 2021

Type: article

Study design: Observational Study

Abstract: A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofab554

Authors: Nicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf, Sara Alosaimy, Dana Holger, Katie Barber, Julie Ann Justo, Kayla Antosz, Travis J Carlson, Jeremy J Frens, Mark Biagi, Wesley D Kufel, William J Moore, Nicholas Mercuro, Brian R Raux, Michael J Rybak

Institutions: Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Medical University of South Carolina, University of Mississippi Medical Center, University of Mississippi, Prisma Health, University of South Carolina, High Point University, Cone Health, Moses H Cone Memorial Hospital, Swedish American Hospital, University of Illinois Chicago, Binghamton University, SUNY Upstate Medical University, Northwestern Memorial Hospital, Beth Israel Deaconess Medical Center, Maine Medical Center, Maine Medical Center, Detroit Medical Center

Language: English

Topic: Antibiotic Resistance in Bacteria

Subfield: Molecular Medicine

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,465

Funders: Melinta Therapeutics, Shionogi, Allergan, National Institute of Allergy and Infectious Diseases

Awards: G1993225747, A Pharmacologic Approach to Prevent Daptomycin Resistance in VRE

OpenAlex ID: W4200364409

FWCI: 2.064

Cites: 26

Cited by: 32

Related to: 10